Figure 6. Antitumor efficacy of irinotecan plus MM151 induction therapy followed by maintenance therapy in LIM1215 xenografts.

(A-B) Mice injected subcutaneously with indicated colon cancer cell lines where treated with irinotecan plus MM151 from week 2 to week 5. Subsequently, from week 5 to week 30 were randomly divided in four groups and treated with indicated drugs. Tumor volume was measured three times per week until week 30 following tumor cell injection. Mice were sacrificed when tumors achieved 2.000 mm³ in size. Values are expressed as mean for each group. Abbreviations: CTR, Control, MEKi, MEK inhibitor; A, median tumor volume (mm³); B, alive mice/total mice; C, number of mice with clinical complete remission. (C-D) Mice were monitored for survival until 30 weeks following tumor cell injection. Differences in animal survival among groups were evaluated by use of the Mantel Cox logrank test. CTR versus MM151, CTR versus MEKi, CTR versus MM151+MEKi, (*** p < 0.05); MM151+MEKi versus MEKi (** p < 0.05); MM151+MEKI versus MM151 (not statistically significant).